



GEORGIA DEPARTMENT
OF COMMUNITY HEALTH

Georgia Department of Community Health

DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health
Zoom Teleconference

August 4, 2020



DRUG UTILIZATION REVIEW BOARD MEETING

AGENDA

Tuesday, August 4, 2020

10:00 a.m. to 2:00 p.m.

EXECUTIVE SESSION	<i>Nina Bandali, PharmD, Pharmacist Account Manager, Magellan Rx Management</i>
CONVENING OF OPEN SESSION AND CALL TO ORDER	<i>Burton L. Lesnick, M.D., FAAP, Chair</i>
MINUTES FROM PREVIOUS MEETING	<i>Chair</i>
EXTERNAL COMMENTS SESSION	<i>Afzal Mistry, PharmD, NorthStar</i>
CLINICAL REVIEWS	<i>Afzal Mistry, PharmD, NorthStar Chad Nicholson, PharmD, NorthStar Emily Baker, PharmD, BCPS, NorthStar</i>
➤ New Drugs	
● Nurtec ODT	
● Reyvow	
● Ubrelvy	
● Vyepiti	
● Vyondys 53	
● Wakix	
BOARD'S RECOMMENDATIONS AND VOTES	<i>Chair</i>
FUTURE AGENDA ITEMS	<i>Chair</i>
ADJOURNMENT OF MEETING	<i>Chair</i>

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Tuesday, May 5, 2020**

MEMBERS PRESENT

Burton L. Lesnick, M.D., FAAP, Chair
M. Celeste Fowler, Pharm.D., Vice-Chair
Gurinder Doad, M.D.
Rod M. Duraski, M.D., FACP, MBA
Glenda Wrenn Gordon, M.D.
Robyn Lorys, Pharm.D.
J. Russell May, Pharm.D.
Osgood (Drew) A. Miller, R.Ph.
Matthew Perri, R.Ph., Ph.D.
Brent L. Rollins, R.Ph., Ph.D.
Danny A. Toth, R.Ph.

MEMBERS ABSENT

Doug Collins, M.D.
Alton Condra III, R.Ph.

Staff

Peter D'Alba, Pharm.D., Pharmacy Director, Pharmacy Services
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services
Rebecca Morrison, Pharmacy Operations Manager, Pharmacy Services
Rose Marie Duncan, MBA, Operations Analyst-Drug Rebate Program, Pharmacy Services
Lori Garner, MHS, MBA, R.Ph., Pharmacist, SHBP

NorthStar HealthCare Consulting

Emily Baker, Pharm.D., BCPS, MHA, MBA, President
Afzal "Fez" Mistry, Pharm.D., Clinical Programs Director
Chad Nicholson, Pharm.D., Clinical Pharmacist

OptumRx

Mark Hall, MBA, PMP, Assoc. Director, Government and Public Sector Markets
Talmahjia "Tami" Sweat, Pharm.D., Director, Clinical Management

Magellan Rx Management

Chris Andrews, Pharm.D., VP, Pharmacy Pricing and Value Based Purchasing
Nina Bandali, Pharm.D., Pharmacist Account Manager
Leslie Pittman, Pharm.D.
Jennifer Costello

Care Management Organizations

Turkesia Robertson-Jones, Pharm.D., CareSource
Charles Kim, Pharm.D., PeachState
Cassandra Tancil, Pharm.D., BCPS Amerigroup

Executive Session

The DUR Board held the Executive Session from 10:05am to 11:12am pursuant to the Open Meetings Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Magellan Rx Management, NorthStar HealthCare Consulting, and OptumRx. CMO representative, Turkesia Robertson-Jones, Pharm.D. (CareSource), also attended the closed session with Board members.

Call to Order

The Drug Utilization Review Board (DURB/DUR Board/Board) held its second meeting for the calendar year virtually on May 5, 2020 via Zoom. The Chair, Burton L. Lesnick, M.D., FAAP, called the meeting to order at 11:25am. Board members were asked to share thoughts and experiences on the COVID-19 pandemic and its effect on their Medicaid patients.

Minutes from the Previous Meeting

Chair Lesnick asked for corrections or changes to the minutes from the February 4, 2020 meeting. Board members approved the minutes as written.

External Comments Session

There were no external comments.

New Drug Reviews

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
Acne and Rosacea Agents, Topical	<i>Aklief</i>	Chad Nicholson, Pharm.D.
Contraceptives, Other	<i>Annovera</i>	Chad Nicholson, Pharm.D.
Macular Degeneration Agents	<i>Beovu</i>	Chad Nicholson, Pharm.D.
Antiparkinson's Agents	<i>Nourianz</i>	Chad Nicholson, Pharm.D.
Biologic Immunomodulators	<i>Rinvoq</i>	Afzal "Fez" Mistry, Pharm.D.
Multiple Sclerosis Agents	<i>Vumerity</i>	Afzal "Fez" Mistry, Pharm.D.
Pleuromutilins	<i>Xenleta</i>	Afzal "Fez" Mistry, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

- Annovera – haven't seen literature supporting continuous use where patient wouldn't have to take it in and out; has potential to be lost with taking it in and out during 13 month cycle; concern of discontinuation due to vaginal itching or bacterial vaginosis;

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES**

Tuesday, May 5, 2020

some may not wash it properly; would be interested to see if there was a higher incidence of bacterial vaginosis in the African-American users.

- Nourianz – concern of vasoconstriction in coronary arteries, so may increase risk of MI; suppresses immune system, so may worsen inflammatory process in body; proposed PA criteria in line with what is usually seen.
- Rinvoq – lab assessment recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids; some interest in using JAK inhibitors in COVID-19.
- Vumerity – proposed PA criteria looks appropriate.

DCH Decisions

DCH Decisions from the February 2020 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

Upcoming Meetings

The following upcoming meetings were published in the DURB binder:

- Drug Utilization Review Board
2 Peachtree Street NW
5th Floor Board Room
Atlanta, Georgia 30303

Tuesday, August 4, 2020

Tuesday, November 3, 2020

Disclosure Forms

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

Board's Recommendations to the Department

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL) or Physician Administered Drug List (PADL) as noted in Attachment A. All motions and votes are noted in Attachment B.

Future Agenda Items

There were no future agenda items noted.

Conclusion

At the conclusion of the open session and no other business for discussion, there was a unanimous decision to adjourn the meeting (motion made by Osgood (Drew) A. Miller, R.Ph. and seconded by J. Russell May, Pharm.D.). Chair Lesnick adjourned the meeting at 1:15pm.

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Tuesday, May 5, 2020**

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE _____
DAY OF _____, 2020.

Burton L. Lesnick, M.D., FAAP, Chair

DRAFT



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
May 5, 2020

Therapeutic Class	Drug Name	DURB Recommendation
Acne and Rosacea Agents, Topical		
	<i>Aklief (Topical) Cream</i>	NP/PA
Contraceptives, Other		
	<i>Anovera (Vaginal) System</i>	NP/PA
Macular Degeneration Agents		
	<i>Beovu (Intravitreal) Injection</i>	P/PA (for coverage on the PADL)
Antiparkinson's Agents		
	<i>Nourianz (Oral) Tablet</i>	NP/PA
Biologic Immunomodulators		
	<i>Rinvoq (Oral) Tablet</i>	NP/PA
Multiple Sclerosis Agents		
	<i>Vumerity (Oral) Capsule</i>	NP/PA
Pleuromutilins		
	<i>Xenleta (Oral) Tablet</i>	NP/PA
	<i>Xenleta (Intravenous) Injection</i>	NP/PA
Antimigraine Agents, Other		
	<i>Ajovy (Subcutaneous) Injection</i>	P/PA
	<i>Emgality (Subcutaneous) Injection</i>	P/PA

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List

Drug Utilization Review Board

Motions - Votes - **New Drugs**

May 5, 2020

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Acne and Rosacea Agents, Topical		Aklief (Topical) Cream	N/A	NP/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.					
3	Doad, Gurinder J.S., M.D.			√		
4	Duraski, Rod, M.D.			√		
5	Fowler, M. Celeste, Pharm.D. - Vice-Chair			√		
6	Gordon, Glenda Wrenn, M.D.			√		
7	Lesnick, Burton, M.D. - Chair			√		
8	Lorys, Robyn Pharm.D.			√		
9	May, J. Russell (Rusty)	√		√		
10	Miller, Osgood (Drew) A., R.Ph.					
11	Perri, Matthew, R.Ph., Ph.D.			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Toth, Danny, R.Ph.		√	√		
			TOTAL	10	0	0

Drug Utilization Review Board

Motions - Votes - **New Drugs**

May 5, 2020

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Contraceptives, Other		Annovera (Vaginal) System	N/A	NP/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.					
3	Doad, Gurinder J.S., M.D.			√		
4	Duraski, Rod, M.D.			√		
5	Fowler, M. Celeste, Pharm.D. - Vice-Chair			√		
6	Gordon, Glenda Wrenn, M.D.			√		
7	Lesnick, Burton, M.D. - Chair			√		
8	Lorys, Robyn Pharm.D.	√		√		
9	May, J. Russell (Rusty)			√		
10	Miller, Osgood (Drew) A., R.Ph.		√			
11	Perri, Matthew, R.Ph., Ph.D.			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Toth, Danny, R.Ph.			√		
			TOTAL	10	0	0

Drug Utilization Review Board

Motions - Votes - **New Drugs**

May 5, 2020

	Drug	PDL Status	Motion - Recommendations	Additional Comments	
New Drug					
Macular Degeneration Agents	Beovu (Intravitreal) Injection	N/A	PADL-P/PA		
Board Members - Present	Motion	Seconded	VOTES		
<i>(Strike out, when absent)</i>	Maker (v)	By (v)	YES (v)	NO (v)	ABSTAIN (v)
1 Collins, Douglas, M.D.					
2 Condra III, Alton, R.Ph.					
3 Doad, Gurinder J.S., M.D.	√		√		
4 Duraski, Rod, M.D.			√		
5 Fowler, M. Celeste, Pharm.D. - Vice-Chair		√	√		
6 Gordon, Glenda Wrenn, M.D.			√		
7 Lesnick, Burton, M.D. - Chair			√		
8 Lorys, Robyn Pharm.D.			√		
9 May, J. Russell (Rusty)			√		
10 Miller, Osgood (Drew) A., R.Ph.					
11 Perri, Matthew, R.Ph., Ph.D.			√		
12 Rollins, Brent L., R.Ph., Ph.D.			√		
13 Toth, Danny, R.Ph.			√		
TOTAL			10	0	0

Drug Utilization Review Board

Motions - Votes - **New Drugs**

May 5, 2020

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antiparkinson's Agents		Nourianz (Oral) Tablet	N/A	NP/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.					
3	Doad, Gurinder J.S., M.D.	√		√		
4	Duraski, Rod, M.D.			√		
5	Fowler, M. Celeste, Pharm.D. - Vice-Chair			√		
6	Gordon, Glenda Wrenn, M.D.			√		
7	Lesnick, Burton, M.D. - Chair			√		
8	Lorys, Robyn Pharm.D.			√		
9	May, J. Russell (Rusty)		√	√		
10	Miller, Osgood (Drew) A., R.Ph.					
11	Perri, Matthew, R.Ph., Ph.D.			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Toth, Danny, R.Ph.			√		
			TOTAL	10	0	0

Drug Utilization Review Board

Motions - Votes - **New Drugs**

May 5, 2020

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Biologic Immunomodulators		Rinvoq (Oral) Tablet	N/A	NP/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.					
3	Doad, Gurinder J.S., M.D.			√		
4	Duraski, Rod, M.D.			√		
5	Fowler, M. Celeste, Pharm.D. - Vice-Chair			√		
6	Gordon, Glenda Wrenn, M.D.			√		
7	Lesnick, Burton, M.D. - Chair			√		
8	Lorys, Robyn Pharm.D.	√		√		
9	May, J. Russell (Rusty)			√		
10	Miller, Osgood (Drew) A., R.Ph.					
11	Perri, Matthew, R.Ph., Ph.D.			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Toth, Danny, R.Ph.		√	√		
			TOTAL	10	0	0

Drug Utilization Review Board

Motions - Votes - **New Drugs**

May 5, 2020

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Multiple Sclerosis Agents		Vumerity (Oral) Capsule	N/A	NP/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.					
3	Doad, Gurinder J.S., M.D.			√		
4	Duraski, Rod, M.D.			√		
5	Fowler, M. Celeste, Pharm.D. - Vice-Chair	√		√		
6	Gordon, Glenda Wrenn, M.D.			√		
7	Lesnick, Burton, M.D. - Chair			√		
8	Lorys, Robyn Pharm.D.			√		
9	May, J. Russell (Rusty)			√		
10	Miller, Osgood (Drew) A., R.Ph.		√			
11	Perri, Matthew, R.Ph., Ph.D.			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Toth, Danny, R.Ph.			√		
			TOTAL	10	0	0

Drug Utilization Review Board

Motions - Votes - **New Drugs**

May 5, 2020

	Drug	PDL Status	Motion - Recommendations	Additional Comments	
New Drug					
Pleuromutilins	Xenleta (Oral) Tablet	N/A	NP/PA		
	Xenleta (Intravenous) Injection	N/A	NP/PA		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>			YES (v)	NO (v)	ABSTAIN (v)
1 Collins, Douglas, M.D.					
2 Condra III, Alton, R.Ph.					
3 Doad, Gurinder J.S., M.D.		√	√		
4 Duraski, Rod, M.D.			√		
5 Fowler, M. Celeste, Pharm.D. - Vice-Chair			√		
6 Gordon, Glenda Wrenn, M.D.			√		
7 Lesnick, Burton, M.D. - Chair			√		
8 Lorys, Robyn Pharm.D.			√		
9 May, J. Russell (Rusty)	√		√		
10 Miller, Osgood (Drew) A., R.Ph.			√		
11 Perri, Matthew, R.Ph., Ph.D.			√		
12 Rollins, Brent L., R.Ph., Ph.D.			√		
13 Toth, Danny, R.Ph.			√		
		TOTAL	11	0	0

Listed below are Preferred Drug List changes for the State of Georgia Fee-For-Service Medicaid and PeachCare for Kids Programs

Effective July 1, 2020 (see chart below)*

DCH rebate vendor Magellan Medicaid Administration (MMA) has reviewed 2020 supplemental rebate offers with DCH and also reviewed specific drug categories at the May 2020 DURB meeting. The PDL/PADL decisions or changes for new drugs or categories reviewed are outlined below. **Those drugs highlighted in red indicate a change from current PDL status.** For a full listing of our PDL, go to www.dch.georgia.gov/pharmacy and select the “preferred product list” option.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ACNE AND ROSACEA AGENTS TOPICAL	
	AKLIEF (TOPICAL)
ANTIBIOTICS, VAGINAL	
NUVESSA (VAGINAL)	
ANTIMIGRAINE AGENTS, OTHER	
AJOVY SYRINGE (SUBCUTANEOUS)	
AJOVY AUTOINJECTOR (SUBCUTANEOUS)	
EMGALITY SYRINGE 120MG (SUBCUTANEOUS)	
EMGALITY PEN (SUBCUTANEOUS)	
ANTIPARASITICS, TOPICAL	
	NATROBA (TOPICAL)
ANTIPARKINSON'S AGENTS	
	NOURIANZ (ORAL)
BIOLOGIC IMMUNOMODULATORS	
	RINVOQ ER (ORAL)
CONTRACEPTIVES, OTHER	
	ANNOVERA (VAGINAL)
ESTROGEN AGENTS, ORAL/TRANSDERMAL	
EVAMIST (TRANSDERM)	
GI MOTILITY, CHRONIC	
MOVANTIK (ORAL)	

PREFERRED AGENTS	NON-PREFERRED AGENTS
MACULAR DEGENERATION AGENTS	
BEOVU (INTRAOCULAR) (PADL)	
MULTIPLE SCLEROSIS AGENTS	
	BETASERON KIT (SUBCUTANE.)
	VUMERITY (ORAL)
PAH AGENTS, ORAL AND INHALED	
	LETAIRIS (ORAL)*
PLEUROMUTILINS	
	XENLETA TABLET (ORAL)
	XENLETA VIAL (INTRAVEN)

*PADL drugs may be subject to a different effective date.

*Effective 5/1/20

**Georgia Department of Community Health (GDCH)
Opportunities for Pharmaceutical Manufacturer Input on Clinical
Recommendations and Clinical Management Strategies by the
Drug Utilization Review Board**

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

Ongoing Opportunity:

DUR Board Meeting Process: Drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via GAMedicaid@nhc-llc.com and reported as appropriate by NHC at subsequent DURB meetings. NHC will pass relevant manufacturer-submitted electronic materials to the DURB members via a secure FTP site.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

Opportunity to Appeal to GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or shodges@dch.ga.gov**

Presentation Opportunity:

Manufacturers' Forum: A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market or a drug that is part of a therapeutic or supplemental rebate class under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at <http://dch.georgia.gov/durb-meeting-information>.

**Questions not addressed in this document may be sent to NorthStar
HealthCare Consulting by e-mail: GAMedicaid@nhc-llc.com**

2020

Upcoming Meetings

Drug Utilization Review Board Meeting

2 Peachtree Street, N.W.

5th Floor Board Room

Atlanta, Georgia 30303

Tuesday, November 3, 2020:

10:00am – 2:00pm

This page intentionally left blank

Drug Utilization Review Board

Board Member	Credentials	Specialty/Area of Expertise	Company Name
Burton L. Lesnick, Chair	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
M. Celeste Fowler, Vice-Chair	Pharm.D., HCMBA	340B Pharmacy	Piedmont Henry Hospital
Douglas C. Collins	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
Alton Condra III	R.Ph.	HIV/AIDS Pharmacy - Infectious Disease Program	Grady Memorial Hospital
Gurinder J.S. Doad	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
Rod M. Duraski	M.D., FACP, MBA	Internal Medicine	West Georgia Health
Glenda Gordon	M.D.	Psychiatry, Academia - Professor	Morehouse School of Medicine
Robyn Lorys	Pharm.D.	Academia - Professor	Mercer University College of Pharmacy
J. Russell May	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
Drew A. Miller	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
Matthew Perri III	Ph.D., R.Ph.	Academia - Professor	University of Georgia College of Pharmacy
Brent L. Rollins	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
Danny A. Toth	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC